NASDAQ:FOCL

FocalTherics (FOCL) Stock Price, News & Analysis

$3.17 -0.07 (-2.16%)
As of 04:00 PM Eastern

About FocalTherics Stock (NASDAQ:FOCL)

Advanced

Key Stats

Today's Range
$3.16
▼
$3.39
50-Day Range
$3.17
▼
$4.74
52-Week Range
$1.95
▼
$6.40
Volume
89,447 shs
Average Volume
63,363 shs
Market Capitalization
$118.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.67
Consensus Rating
Moderate Buy

Company Overview

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.

FocalTherics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

FOCL MarketRank™: 
2.56108897742 of 5 stars

FocalTherics scored higher than 51% of companies evaluated by MarketBeat, and ranked 530th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    FocalTherics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.

  • Upside Potential

    FocalTherics has a consensus price target of $9.67, representing about 204.9% upside from its current price of $3.17.

  • Amount of Analyst Coverage

    FocalTherics has only been the subject of 2 research reports in the past 90 days.

  • Read more about FocalTherics' stock forecast and price target.
  • Earnings Growth

    Earnings for FocalTherics are expected to grow in the coming year, from ($0.71) to ($0.56) per share.

  • Price to Book Value per Share Ratio

    FocalTherics has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.08% of the float of FocalTherics has been sold short.
  • Short Interest Ratio / Days to Cover

    FocalTherics has a short interest ratio ("days to cover") of 9.37.
  • Change versus previous month

    Short interest in FocalTherics has recently increased by 9.14%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    FocalTherics does not currently pay a dividend.

  • Dividend Growth

    FocalTherics does not have a long track record of dividend growth.

  • News Sentiment

    FocalTherics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for FocalTherics this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    5 people have added FocalTherics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, FocalTherics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.10% of the stock of FocalTherics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    62.74% of the stock of FocalTherics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about FocalTherics' insider trading history.
Receive FOCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FocalTherics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FOCL Stock News Headlines

HC Wainwright Increases Earnings Estimates for FocalTherics
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
FocalTherics (NASDAQ:FOCL) Raised to Hold at Wall Street Zen
EDAP TMS (FOCL) Q3 2026 Earnings Call Transcript
FocalTherics™ Reports Third Quarter 2026 Financial Results
See More Headlines

FOCL Stock Analysis - Frequently Asked Questions

FocalTherics' stock was trading at $4.65 on June 2, 2026. Since then, FOCL stock has decreased by 31.8% and is now trading at $3.17.

FocalTherics (NASDAQ:FOCL) released its quarterly earnings data on Thursday, November, 5th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.08. The firm earned $9.83 million during the quarter. FocalTherics had a negative trailing twelve-month return on equity of 223.32% and a negative net margin of 59.77%.
Read the conference call transcript
.

Shares of FOCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that FocalTherics investors own include OPKO Health (OPK), Riot Platforms (RIOT), Solid Biosciences (SLDB), Intel (INTC), MannKind (MNKD), ExxonMobil (XOM) and Plug Power (PLUG).

Company Calendar

Last Earnings
11/05/2026
Today
11/16/2026
38th Annual Healthcare Conference
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:FOCL
Previous Symbol
NASDAQ:EDAP
CIK
1041934
Employees
230
Year Founded
N/A

Price Target and Rating

High Price Target
$15.00
Low Price Target
$4.00
Potential Upside/Downside
+204.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.98)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$29.25 million
Net Margins
-59.77%
Pretax Margin
-59.21%
Return on Equity
-223.32%
Return on Assets
-41.32%

Debt

Debt-to-Equity Ratio
0.98
Current Ratio
2.63
Quick Ratio
2.40

Sales & Book Value

Annual Sales
$70.53 million
Price / Sales
1.69
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.96 per share
Price / Book
3.30

Miscellaneous

Outstanding Shares
37,530,000
Free Float
33,738,000
Market Cap
$118.97 million
Optionable
Optionable
Beta
-0.02
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:FOCL) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners